Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92nd Congress...
Daniel Gaudet Coll Cardiol Gugliucciaj Clin Robert Rosenson Christiem Ballantyne Baylor College Of Medicine
Source: marketscreener.com